Phillip Madonia, MD
Nephrology · Alabaster, ALNPI 1245440585
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $146,436 of the $165,289 with a category attached, or 88.6%. 23 manufacturers reported payments, led by Vifor Pharma, Inc. at 30.3% of the total. Among nephrology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 296 payments — averaging $558.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$50K
- Bayer$41K
- Boehringer Ingelheim$29K
- AstraZeneca$17K
- Lilly USA, LLC$15K
- Mallinckrodt Enterprises LLC$10K
- plus $2K from 17 others
Across 10 payments — averaging $31,023 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$202K
- Eli Lilly$82K
- AstraZeneca$26K
What the payments were for
- Consulting fees$4,2523%
- Speaking & faculty fees$146,43689%
- Travel & lodging$7,6965%
- Food & beverage$6,8864%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 72 | $50,094 |
| Bayer | 45 | $41,336 |
| Boehringer Ingelheim | 39 | $29,428 |
| AstraZeneca(2 entities) | 49 | $17,499 |
| Lilly USA, LLC | 19 | $14,523 |
| Mallinckrodt Enterprises LLC | 14 | $9,972 |
| Mozarc Medical US LLC | 6 | $576 |
| Medtronic | 5 | $453 |
| Bard Peripheral Vascular, Inc. | 4 | $398 |
| Calliditas Therapeutics US Inc. | 3 | $163 |
| Hologic Sales And Service, LLC | 1 | $150 |
| Travere Therapeutics, Inc. | 7 | $114 |
| Fresenius USA Marketing, Inc. | 6 | $106 |
| Mallinckrodt Hospital Products Inc. | 6 | $106 |
| Akebia Therapeutics Inc | 4 | $90 |
| Otsuka America Pharmaceutical, Inc. | 3 | $70 |
| Aurinia Pharma U.S., Inc. | 3 | $53 |
| Amgen | 3 | $48 |
| BD | 2 | $35 |
| OPKO Pharmaceuticals, LLC | 2 | $28 |
| Novo Nordisk | 1 | $19 |
| AbbVie | 1 | $14 |
| GSK | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$165,289 in reported general payments places this provider in the 95th percentile of 164 nephrology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JynarqueTolvaptan | 13 | $246,071 |
| FarxigaDapagliflozin Propanediol | 156 | $114,281 |
| VelphoroSucroferric Oxyhydroxide | 16 | $24,993 |
| KerendiaFinerenone | 24 | $19,409 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 63 | $14,565 |
| JardianceEmpagliflozin | 23 | $13,549 |
| Nifedipine ErNifedipine | 149 | $2,883 |
| Losartan Potassium | 98 | $933 |
| Tamsulosin Hcl | 106 | $836 |
| Calcitriol | 29 | $808 |
| Allopurinol | 24 | $580 |
| Amlodipine Besylate | 62 | $438 |
| Furosemide | 72 | $414 |
| Potassium Chloride | 13 | $382 |
| Irbesartan | 12 | $339 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Jynarque | $70 | $246,07113 claims |
| AstraZenecaFarxiga | $17,499 | $114,281156 claims |
| Fresenius USA Marketing, Inc.Velphoro | $106 | $24,99316 claims |
| BayerKerendia | $41,336 | $19,40924 claims |
| Boehringer IngelheimJardiance | $29,428 | $13,54923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 164 nephrology providers in Alabama.
Other nephrology in Alabaster
- Michael QuadriniHuntsville$323K
- Dana RizkBirmingham$196K
- Sumeet MunjalMontgomery$191K
- Eric WallaceBirmingham$172K
- Thomas OzbirnHomewood$133K
- David WarnockBirmingham$128K
- Jeffrey GlazeHomewood$98K
- Michal MrugBirmingham$73K
- Vineeta KumarBirmingham$59K
- Ashita TolwaniBirmingham$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.